Title: CIRRHOSIS IN INTRAHEPATIC CHOLANGIOCARCINOMA: PROGNOSTIC
IMPORTANCE AND IMPACT ON SURVIVAL
Version: 10 Date: 13 Nov 2022
Reviewer's report:
The study period and study population need to be described more clearly. The initial draft of the
manuscript reported that during the study period of 2010-2017, there were 53,054 patients with
CCA of whom 33,160 had intrahepatic CCA and 3,644 of the patients with iCCA underwent
a liver biopsy. In the current paper, the study period is reported to be from 2004-2017 but the
number of patients are the same despite expanding the study period. I’m assuming this was a
typo but just wanted to double check. Second, the study population and the patient flow figure
should be edited to enhance clarity. In the results section of the abstract (lines 52-53), the authors
report that there were 33,160 people with CCA, of whom 3,644 had intrahepatic CCA. In the
results section of the manuscript (line 142), they again state that 3,644 represents the number of
people with iCCA. In the limitations section (lines 309-310), they suggest that 33,160 represents
the number of people with iCCA and 3,644 represents the number of individuals that underwent
a liver biopsy. The patient flow diagram is a nice addition to the paper but should be revised to
enhance clarity and should include the study period. For example, “33,160 patients with iCCA
in NCDB (2004-2017) -> 3,644 patients with iCCA that underwent a liver biopsy -> 1,052 with
cirrhosis” etc.
The results section is redundant, with much of the information in the tables being reported in
the results section, and could be condensed.
There should be mention of the fact that only 3,030 patients had survival data available for
analysis and what proportion died during the study period. While the authors state this at the end
of their limitations section, it should be mentioned in the results section for greater transparency.
Lastly, the authors should state which variables were included in the final model and why.
Title: CIRRHOSIS IN INTRAHEPATIC CHOLANGIOCARCINOMA: PROGNOSTIC
IMPORTANCE AND IMPACT ON SURVIVAL
Version: 10 Date: 13 Nov 2022
Reviewer's report:
The study period and study population need to be described more clearly. The initial draft of the
manuscript reported that during the study period of 2010-2017, there were 53,054 patients with
CCA of whom 33,160 had intrahepatic CCA and 3,644 of the patients with iCCA underwent
a liver biopsy. In the current paper, the study period is reported to be from 2004-2017 but the
number of patients are the same despite expanding the study period. I’m assuming this was a
typo but just wanted to double check. Second, the study population and the patient flow figure
should be edited to enhance clarity. In the results section of the abstract (lines 52-53), the authors
report that there were 33,160 people with CCA, of whom 3,644 had intrahepatic CCA. In the
results section of the manuscript (line 142), they again state that 3,644 represents the number of
people with iCCA. In the limitations section (lines 309-310), they suggest that 33,160 represents
the number of people with iCCA and 3,644 represents the number of individuals that underwent
a liver biopsy. The patient flow diagram is a nice addition to the paper but should be revised to
enhance clarity and should include the study period. For example, “33,160 patients with iCCA
in NCDB (2004-2017) -> 3,644 patients with iCCA that underwent a liver biopsy -> 1,052 with
cirrhosis” etc.
The results section is redundant, with much of the information in the tables being reported in
the results section, and could be condensed.
There should be mention of the fact that only 3,030 patients had survival data available for
analysis and what proportion died during the study period. While the authors state this at the end
of their limitations section, it should be mentioned in the results section for greater transparency.
Lastly, the authors should state which variables were included in the final model and why.
Please review this paper.
user
Title: CIRRHOSIS IN INTRAHEPATIC CHOLANGIOCARCINOMA: PROGNOSTIC
IMPORTANCE AND IMPACT ON SURVIVAL
Version: 10 Date: 13 Nov 2022
Reviewer's report:
The study period and study population need to be described more clearly. The initial draft of the
manuscript reported that during the study period of 2010-2017, there were 53,054 patients with
CCA of whom 33,160 had intrahepatic CCA and 3,644 of the patients with iCCA underwent
a liver biopsy. In the current paper, the study period is reported to be from 2004-2017 but the
number of patients are the same despite expanding the study period. I’m assuming this was a
typo but just wanted to double check. Second, the study population and the patient flow figure
should be edited to enhance clarity. In the results section of the abstract (lines 52-53), the authors
report that there were 33,160 people with CCA, of whom 3,644 had intrahepatic CCA. In the
results section of the manuscript (line 142), they again state that 3,644 represents the number of
people with iCCA. In the limitations section (lines 309-310), they suggest that 33,160 represents
the number of people with iCCA and 3,644 represents the number of individuals that underwent
a liver biopsy. The patient flow diagram is a nice addition to the paper but should be revised to
enhance clarity and should include the study period. For example, “33,160 patients with iCCA
in NCDB (2004-2017) -> 3,644 patients with iCCA that underwent a liver biopsy -> 1,052 with
cirrhosis” etc.
The results section is redundant, with much of the information in the tables being reported in
the results section, and could be condensed.
There should be mention of the fact that only 3,030 patients had survival data available for
analysis and what proportion died during the study period. While the authors state this at the end
of their limitations section, it should be mentioned in the results section for greater transparency.
Lastly, the authors should state which variables were included in the final model and why.
assistant